Lyell Immunopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lyell Immunopharma Inc (LYEL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lyell Immunopharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 4,313M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-40.7% annualized vs trailing 12 months), vs accelerating (+7.2%) for its tracked peer group.
- Growth: Lyell Immunopharma Inc generated -50.0% revenue growth year over year in Q2 2026, vs 12.3% for its tracked competitors combined.
- Profitability: Its -1,118,875.0% net margin compares with 10.2% for the peer group.
- Scale: Lyell Immunopharma Inc ranks #245 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Lyell Immunopharma Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.00M compares with $0.32M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LYEL Sales vs. its Competitors, Q2 2026
Lyell Immunopharma Inc reported revenue contraction of 50.00 % year on year in Q2 2026, below its competitors' combined revenue growth of 12.30 %.
With a net margin of -1,118,875.00 %, Lyell Immunopharma Inc reported lower profitability than its competitors (10.20 %).
Lyell Immunopharma Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Lyell Immunopharma Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lyell Immunopharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lyell Immunopharma Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lyell Immunopharma Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -50.0% for Lyell Immunopharma Inc. Lyell Immunopharma Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Lyell Immunopharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lyell Immunopharma Inc | No | No | No | Yes |
| Competitors combined (8) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LYEL Stock Performance relative to its Competitors
LYEL Stock Performance relative to High-Confidence Competitors
LYEL Stock Performance relative to Similar-Size Competitors
LYEL Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Precigen Inc | 282.9% | Outperformed |
| 2 | Allegion Plc | 282.9% | Outperformed |
| 3 | Genelux Corporation | 282.9% | Outperformed |
| 4 | Caribou Biosciences Inc | 282.9% | Outperformed |
| 5 | Instil Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lyell Immunopharma Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lyell Immunopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Lyell Immunopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lyell Immunopharma Inc | 225.00 | 0.03 |
| Allegion Plc | 13,366.98 | 4,288.50 |
| Precigen Inc | 2,852.04 | 31.60 |
| Sensei Biotherapeutics Inc | 129.06 | - |
| Caribou Biosciences Inc | 125.22 | 10.04 |
| Genelux Corporation | 110.15 | - |
| SUBTOTAL | 16,880.95 | 4,409.36 |
Sign in to see all competitors of Lyell Immunopharma Inc .
Sources: Lyell Immunopharma Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lyell Immunopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lyell Immunopharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Instil Bio Inc | Named by the company | 85% |
| Allogene Therapeutics Inc | Named by the company | 85% |
| Fred Hutchinson Cancer Center | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
| Fred Hutch | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
| Precigen Inc | Named by the company | 85% |
| Senti Biosciences Holdings Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Lyell Immunopharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Lyell Immunopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Lyell Immunopharma Inc | Reportable segment 100.00 % |
| Allegion Plc | Allegion Americas 79.77 % |
| Precigen Inc | Reportable 100.00 % |
| Caribou Biosciences Inc | Reportable 100.00 % |
| Senti Biosciences Holdings Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Lyell Immunopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lyell Immunopharma Inc | 225 | 168 | -1,543,335 |
| Allegion Plc | 13,367 | 322,444 | 49,519 |
| Precigen Inc | 2,852 | 197,469 | -1,277,613 |
| Sensei Biotherapeutics Inc | 129 | - | -6,742,345 |
| Caribou Biosciences Inc | 125 | 103,454 | -1,066,010 |
| Genelux Corporation | 110 | - | -1,369,077 |
| PEERS TOTAL | 16,656 | 316,899 | -9,339 |
Sign in to see all peers for Lyell Immunopharma Inc .
Lyell Immunopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Caribou Biosciences Inc | United States 94.16 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Lyell Immunopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Lyell Immunopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Lyell Immunopharma Inc ranks #245 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 245 | Lyell Immunopharma Inc | 225 | 0.00 % |
Market cap and industry share for the rest of Lyell Immunopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Lyell Immunopharma Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 240 | Foghorn Therapeutics Inc | 247 | -27.98 % |
| 241 | Lifecore Biomedical Inc | 245 | -6.99 % |
| 242 | Akebia Therapeutics Inc | 242 | -67.27 % |
| 243 | Nature s Sunshine Products inc | 234 | -19.73 % |
| 244 | Sionna Therapeutics Inc | 1,234 | 12.3% |
| 245 | Lyell Immunopharma Inc | 225 | -25.02 % |
| 246 | Keros Therapeutics Inc | 1,234 | 12.3% |
| 247 | Camp4 Therapeutics Corporation | 1,234 | 12.3% |
| 248 | An2 Therapeutics Inc | 1,234 | 12.3% |
| 249 | Cartesian Therapeutics Inc | 1,234 | 12.3% |
| 250 | Oramed Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Lyell Immunopharma Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Lyell Immunopharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 64.89 % (avg) | - |
| Operating Margin | -949,981.48 % | industry median | -949,927.8 pp |
| EBITDA Margin | -721,500.00 % | -7.21 % (avg) | -721,492.8 pp |
| Capital Intensity (Capex / Revenue) | 2,633.33 % | 4.92 % (avg) | +2,628.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lyell Immunopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 1.3x | 4.5x | -3.2x |
| Return on Equity | -91.62 % | industry aggregate | -108.87 % |
| Return on Invested Capital | -43.91 % | -2.95 % (avg) | -40.96 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lyell Immunopharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | -99.85 % | -53.08 % | -40.98 % |
| Operating Margin | - | -220.89 % | -190,006.15 % | -588,122.95 % | -748,344.44 % |
| Return on Invested Capital | - | -10.35 % | -16.47 % | -32.68 % | -41.18 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lyell Immunopharma Inc's Strategic Group Map
Every company in Lyell Immunopharma Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Lyell Immunopharma Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Lyell Immunopharma Inc's BCG Growth-Share Matrix
Relative market share (vs Lyell Immunopharma Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Lyell Immunopharma Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Lyell Immunopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 2,633.33 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Lyell Immunopharma Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Lyell Immunopharma Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Lyell Immunopharma Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Lyell Immunopharma Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Lyell Immunopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 949,927.8 points below the industry median.
- Return on equity 108.9 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-40.7% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lyell Immunopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lyell Immunopharma Inc | 2.20 | 6.77 | - |
| Allegion Plc | 0.32 | 1.86 | 0.99 |
| Precigen Inc | 0.58 | 3.60 | 6.05 |
| Sensei Biotherapeutics Inc | 6.11 | 13.56 | - |
| Caribou Biosciences Inc | 1.64 | 5.92 | - |
| Genelux Corporation | 1.49 | 3.10 | - |
Sign in to see all peers for Lyell Immunopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lyell Immunopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lyell Immunopharma Inc | Q2 2026 | -50.0 % | - |
| Allegion Plc | Q2 2026 | +12.7 % | +15.6 % |
| Precigen Inc | Q1 2026 | +1,633.9 % | - |
| Sensei Biotherapeutics Inc | Q2 2026 | - | - |
| Caribou Biosciences Inc | Q2 2026 | -43.8 % | - |
| Genelux Corporation | Q2 2026 | - | - |
| PEERS TOTAL | +2.9 % | +16.8 % |
Sign in to see all peers for Lyell Immunopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lyell Immunopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lyell Immunopharma Inc | Q2 2026 | - | +52.4 % |
| Allegion Plc | Q2 2026 | +14.1 % | +1.1 % |
| Precigen Inc | Q1 2026 | +132.6 % | -58.5 % |
| Sensei Biotherapeutics Inc | Q2 2026 | - | - |
| Caribou Biosciences Inc | Q2 2026 | - | -99.8 % |
| Genelux Corporation | Q2 2026 | - | +1,232.2 % |
Sign in to see all peers for Lyell Immunopharma Inc .
Lyell Immunopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lyell Immunopharma Inc | - | - | - |
| Allegion Plc | 12.47% | 14.48% | 31.99% |
| Precigen Inc | - | - | - |
| Sensei Biotherapeutics Inc | - | - | - |
| Caribou Biosciences Inc | - | - | - |
| Genelux Corporation | - | - | - |
Sign in to see all peers for Lyell Immunopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lyell Immunopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lyell Immunopharma Inc | - | 8,333.16 |
| Allegion Plc | 20.36 | 3.12 |
| Precigen Inc | - | 90.27 |
| Sensei Biotherapeutics Inc | - | - |
| Caribou Biosciences Inc | - | 12.48 |
| Genelux Corporation | - | - |
| PEERS AVERAGE | - | 3.83 |
Sign in to see all peers for Lyell Immunopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.